The Mumbai based leading pharmaceutical company Ajanta Pharma Ltd has entered into the Brazilian market with the first shipment just sent last week. It has tied up with a leading Canadian pharmaceutical group, Arrow Pharmaceuticals for marketing Nimesulide in Brazil. The company is targeting "Speciality" specialist on various therapeutic areas, with the launch of several new products in the cardiology, dermatology, ophthalmology and ENT segment for the domestic market.
Ajanta Pharma Ltd has transformed itself into a "Speciality" specialist over the last 5 years. The company has decided to focus on speciality segment with the launch of cardiology division with a few first to market products. A series of speciality divisions were launched subsequently focussing on ophthalmology, dermatology and ENT. All the products in these speciality divisions are unique in terms of their innovative delivery solutions and combinations for the patient convenience and compliance. The company is amongst the first few in the country to launch second division for Ophthalmology and Dermatology and first to launch a dedicated ENT division.
Commenting on the development, Yogesh Agrawal, executive director, said, "Brazil is among large pharma markets of the world. With entry into Brazil, our presence in the Latin American market has strengthened substantially. The tie up with Arrow Group, which has a strong presence in the Brazilian market, will enable us to reach the patients in the market very widely. We are planning to file 10-12 new dossiers in Brazil by the end of 2008".
Agrawal further said, "We have now become a Speciality specialist. In the last 5 years we have launched 7 speciality divisions, with many new 1st of its kind product in the market. We have developed excellent capabilities in house to identify the gaps in the patient care in speciality segments and develop products in our R&D to fill this gap. This ensures higher patient compliance and maximum convenience to the ailing patients."
"Products like Dospin, Met XL, Gate eye drop, Vaniza, are few examples of our product innovation in terms of NDDS and are enjoying leadership in their sub therapeutic areas. Currently, we are ranked 6th in terms of number of prescription in ophthalmology segment as per IMS ORG," he added.
Ajanta Pharma is concentrating on chronic therapies where treatment period of patients extends beyond three months. It is one of the fastest growing companies in its segments due to its focused approach. The multiple dosages and combinations meet the requirements of different class of patients thereby enabling the servicing of entire spectrum.
The company focuses on brand building across the world and has presence in Asia, Africa, Middle East and CIS across 50 countries in these regions.